Latest news
AB2 Bio receives USD 30 million from Nippon Shinyaku - Greater Geneva Bern area (GGBa)Greater Geneva Bern area (GGBa) · Mon, 03 Aug 2026 12:07:14 GMTAB2 Bio Receives $30 Million From Nippon Shinyaku For U.S. Tadekinig Alfa Rights, With Up To $600 Million In Milestones And Royalties - Pulse 2.0Pulse 2.0 · Mon, 03 Aug 2026 01:58:58 GMTKorro Bio, Inc. (NASDAQ:KRRO) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeatMarketBeat · Sun, 02 Aug 2026 06:30:03 GMTINmune Bio receives ~$4.6M in R&D rebates, cash proceeds exceed Q2 operating cash use - TradingViewTradingView · Fri, 31 Jul 2026 20:13:01 GMTINmune Bio receives $4.6M in R&D rebates from Australia, UK - Investing.comInvesting.com · Fri, 31 Jul 2026 11:46:12 GMTINmune Bio Receives R&D Rebates of Approximately $4.6 Million - Yahoo FinanceYahoo Finance · Fri, 31 Jul 2026 11:00:00 GMTBio-Thera Solutions Receives $2.3 Million in Milestone Payments for Arthritis Drug - MoomooMoomoo · Thu, 30 Jul 2026 07:00:00 GMTAB2 Bio receives $30 million from Nippon Shinyaku for exclusive U.S. commercialization rights to Tadekinig Alfa - The Manila TimesThe Manila Times · Thu, 30 Jul 2026 06:37:58 GMT